The company said the proposed merger is expected to be Ebitda margin accretive and deleverage SeQuent's balance sheet.fle
The rise in the share price came after the company announced that it has received World Health Organisation (WHO) prequalification approval for Albendazole Active Pharmaceutical Ingredient (API).